| Medium |
Basal Media |
Serum |
Supplementation |
| Control (FBS-M, HS-M, SF/XF- M) |
DMEM/F-12, SF/XF-M |
10% FBS or 15% HS or no serum |
None |
| Osteogenic Medium (OM; FBS-OM, HS-OM, SF/XF-OM) |
DMEM/F-12, SF/XF-M |
10% FBS or |
50 µM L- ascorbic acid (Sigma), 10 |
| 15% HS or no |
mM beta glycerophosphate (Sigma), |
| serum |
100nM 1,25 hydroxy Vitamin D3 |
| |
(VD; Sigma), 1% a/a, 1% GlutaMAX |
| Adipogenic Medium (AM; FBS-AM, HS-AM, SF/XF-AM) |
DMEM/F-12, SF/XF-M |
10% FBS or 15% HS or no serum |
33 µM biotin (Sigma) 1µM |
| dexamethasone (Sigma), 100 nM |
| insulin (life technologies), 17 µM |
| pantothenate (Fluka), 1% GlutaMAX, |
| and 1% a/a. Upon seeding of cells, |
| 250 µM of isobutylmethylxanthine |
| (IBMX; Sigma) was added for 72 |
| hours |
| Chondrogenic Medium (CM) |
DMEM/F-12, SF/XF-M |
No serum |
Insulin Transferrin-Selenium+1 |
| (Sigma), 50 µM L- ascorbic acid, |
| 55µM sodium pyruvate (Life |
| Technologies), 23 µM L-proline |
| (Sigma), 1% GlutaMAX and 1% a/a. |
| TGF-β1 (Sigma) |
